Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.
Eli Lilly has acquired Engage Bio and its preclinical, non-viral DNA delivery platform. Credit: Tada Images / Shutterstock.com.
Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics for up to $202m in cash, marking another addition to the company’s growing genetic medicines roster.
At the centrepiece of this deal is Engage’s preclinical non-viral DNA delivery platform, Tethosome, which the biotech has designed in a bid to sidestep the tolerability, potency and redosability challenges faced by other DNA delivery methods. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
